Post by Gen Era Diagnostics

How can you maximize the clinical power of #cfDNA analysis? With MSK-ACCESS® powered with SOPHiA DDM™, the answer is clear.   Liquid biopsy brings new challenges and MSK-ACCESS® helps overcome them with accuracy, speed, and confidence.   Developed by Memorial Sloan Kettering Cancer Center and powered with SOPHiA GENETICS, MSK-ACCESS® provides a decentralized, highly sensitive cfDNA assay designed to support precision #oncology research. The assay leverages advanced bioinformatics, matched tumor-normal analysis, and robust variant detection to address the complexities of cfDNA-based testing.   Unlike conventional approaches, MSK-ACCESS® powered with #SOPHiADDM integrates multiple variant classes and supports longitudinal monitoring, helping researchers generate actionable insights for patient care.   👉 Swipe to explore the key features that differentiate MSK-ACCESS®.   🔗 Learn more: https://lnkd.in/dbvGZKF5